Vericel Co. (NASDAQ:VCEL) Receives $48.17 Consensus Target Price from Brokerages

Vericel Co. (NASDAQ:VCEL) has received an average recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the last year is $48.17.

VCEL has been the subject of several research analyst reports. TD Cowen initiated coverage on shares of Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 price objective for the company. HC Wainwright boosted their price objective on shares of Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Truist Financial reaffirmed a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. Finally, StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, June 21st.

Vericel Stock Down 2.2 %

Shares of NASDAQ:VCEL opened at $45.88 on Friday. The stock has a market cap of $2.23 billion, a PE ratio of -4,583.42 and a beta of 1.74. The business has a 50 day moving average of $46.58 and a 200-day moving average of $44.49. Vericel has a 12-month low of $30.18 and a 12-month high of $53.05.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The business had revenue of $51.28 million during the quarter, compared to analysts’ expectations of $49.07 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. Equities research analysts expect that Vericel will post 0.11 earnings per share for the current year.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total value of $772,100.00. Following the completion of the sale, the chief executive officer now owns 220,752 shares in the company, valued at approximately $9,739,578.24. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Sean C. Flynn sold 6,772 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the completion of the transaction, the insider now directly owns 487 shares of the company’s stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $44.12, for a total transaction of $772,100.00. Following the completion of the transaction, the chief executive officer now directly owns 220,752 shares of the company’s stock, valued at $9,739,578.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,246 shares of company stock worth $1,924,869. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. MCF Advisors LLC boosted its holdings in Vericel by 86.1% in the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 223 shares during the period. Arcadia Investment Management Corp MI bought a new position in Vericel in the 1st quarter valued at $27,000. DekaBank Deutsche Girozentrale bought a new position in Vericel in the 4th quarter valued at $33,000. GAMMA Investing LLC bought a new position in Vericel in the 4th quarter valued at $65,000. Finally, Lazard Asset Management LLC boosted its holdings in Vericel by 178.7% in the 1st quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,657 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.